Strategic partnerships Halozyme’s ENHANZE technology is already licensed to top pharma partners (Roche, Pfizer, Janssen, AbbVie, Eli Lilly, BMS, Alexion, argenx) and is being expanded through recent collaborations with GSK and Incyte, presenting multiple upsell opportunities to broaden existing license scopes or introduce adjacent subcutaneous delivery applications.

Oncology focus Recent news highlights Halozyme’s emphasis on novel oncology treatments and subcutaneous formulations, signaling strong demand for enabling subcutaneous delivery in cancer therapies and clear opportunities to position ENHANZE as a value-add for oncology portfolios.

Revenue growth With revenue in the mid hundreds of millions and recent earnings beats, Halozyme demonstrates robust financial health and growing adoption of ENHANZE in global markets, suggesting a favorable environment for expanding collaborations and co-development opportunities.

Global scale Halozyme has commercialization in over 100 markets and a diversified partner ecosystem, indicating sales opportunities across geographies and the potential to support global launches of new subcutaneous formulations, especially in large mature markets seeking improved patient experience.

Talent and capacity A sizable workforce and a culture focused on mission alignment imply capacity for additional partnerships and capability expansion, enabling BD teams to pursue new licensing deals, technology integrations, or joint development programs without overextending operations.